A novel mouse model of chronic suppurative otitis media and its use in preclinical antibiotic evaluation.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
08 2020
Historique:
received: 10 04 2020
accepted: 02 07 2020
entrez: 28 8 2020
pubmed: 28 8 2020
medline: 12 4 2022
Statut: epublish

Résumé

Chronic suppurative otitis media (CSOM) is a neglected pediatric disease affecting 330 million worldwide for which no new drugs have been introduced for over a decade. We developed a mouse model with utility in preclinical drug evaluation and antimicrobial discovery. Our model used immune-competent mice, tympanic membrane perforation and inoculation with luminescent Pseudomonas aeruginosa that enabled bacterial abundance tracking in real-time for 100 days. The resulting chronic infection exhibited hallmark features of clinical CSOM, including inhibition of tympanic membrane healing and purulent ear discharge. We evaluated the standard care fluoroquinolone ofloxacin and demonstrated that this therapy resulted in a temporary reduction of bacterial burden. These data are consistent with the clinical problem of persistent infection in CSOM and the need for therapeutic outcome measures that assess eradication post-therapeutic endpoint. We conclude that this novel mouse model of CSOM has value in investigating new potential therapies.

Identifiants

pubmed: 32851190
doi: 10.1126/sciadv.abc1828
pii: abc1828
pmc: PMC7428333
doi:

Substances chimiques

Anti-Bacterial Agents 0
Ofloxacin A4P49JAZ9H

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

eabc1828

Informations de copyright

Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution NonCommercial License 4.0 (CC BY-NC).

Références

Eur Arch Otorhinolaryngol. 2009 Feb;266(2):221-4
pubmed: 18629531
Curr Opin Microbiol. 2013 Oct;16(5):580-9
pubmed: 23880136
Expert Rev Anti Infect Ther. 2018 Jan;16(1):51-65
pubmed: 29235402
Nat Commun. 2019 Mar 12;10(1):1177
pubmed: 30862812
Am J Otolaryngol. 2011 Jan-Feb;32(1):32-7
pubmed: 20036033
Exp Dermatol. 2010 Feb;19(2):154-6
pubmed: 19650869
PLoS Negl Trop Dis. 2015 Mar 26;9(3):e0003485
pubmed: 25811602
Front Cell Neurosci. 2019 Feb 27;13:60
pubmed: 30873008
Front Microbiol. 2019 Nov 13;10:2603
pubmed: 31798554
FEMS Microbiol Lett. 2004 Jan 15;230(1):13-8
pubmed: 14734160
Microbiol Mol Biol Rev. 2014 Sep;78(3):510-43
pubmed: 25184564
Science. 2017 Feb 24;355(6327):826-830
pubmed: 28183996
Infect Immun. 2007 Aug;75(8):3715-21
pubmed: 17562773
Can J Microbiol. 2012 Aug;58(8):1027-34
pubmed: 22838838
Laryngoscope. 2005 Aug;115(8):1469-72
pubmed: 16094127
Eur Arch Otorhinolaryngol. 2014 Nov;271(11):2877-83
pubmed: 24132653
Antimicrob Agents Chemother. 2018 Aug 27;62(9):
pubmed: 29967020
Nagoya J Med Sci. 2017 Feb;79(1):1-7
pubmed: 28303055
J Bacteriol. 2010 Dec;192(23):6191-9
pubmed: 20935098
Otol Neurotol. 2016 Aug;37(7):838-46
pubmed: 27273405
Wound Repair Regen. 2007 Jul-Aug;15(4):450-8
pubmed: 17650087
PLoS Biol. 2010 Feb 23;8(2):e1000317
pubmed: 20186264
Tissue Eng Part A. 2015 May;21(9-10):1483-94
pubmed: 25567607
JAMA. 2008 Jun 11;299(22):2682-4
pubmed: 18544729
Acta Otolaryngol. 2016;136(1):12-7
pubmed: 26381832
Indian J Otolaryngol Head Neck Surg. 2013 Dec;65(Suppl 3):557-61
pubmed: 24427714
J Bacteriol. 2001 Dec;183(23):6746-51
pubmed: 11698361
Appl Environ Microbiol. 2013 Jul;79(13):4149-53
pubmed: 23584769
J Clin Microbiol. 2016 Oct;54(10):2538-46
pubmed: 27487953
Eur Ann Otorhinolaryngol Head Neck Dis. 2018 Jun;135(3):183-190
pubmed: 29656888
Nat Protoc. 2006;1(1):153-61
pubmed: 17406227
PLoS Pathog. 2019 Apr 10;15(4):e1007696
pubmed: 30970038
Nat Methods. 2005 Jun;2(6):443-8
pubmed: 15908923
Antonie Van Leeuwenhoek. 2016 Jun;109(6):737-53
pubmed: 26995781
Otol Neurotol. 2008 Dec;29(8):1056-60
pubmed: 18833010
Clin Ther. 1998 Jul-Aug;20(4):744-59
pubmed: 9737834
mBio. 2017 Feb 28;8(1):
pubmed: 28246361

Auteurs

Kelly M Khomtchouk (KM)

Department of Otolaryngology, Head and Neck Surgery, Stanford University, Stanford, CA, USA.

Ali Kouhi (A)

Department of Otolaryngology, Head and Neck Surgery, Stanford University, Stanford, CA, USA.
Department of Otolaryngology, Head and Neck Surgery, Tehran University of Medical Sciences, Tehran, Iran.

Anping Xia (A)

Department of Otolaryngology, Head and Neck Surgery, Stanford University, Stanford, CA, USA.

Laurent Adonis Bekale (LA)

Department of Otolaryngology, Head and Neck Surgery, Stanford University, Stanford, CA, USA.

Solange M Massa (SM)

Department of Otolaryngology, Head and Neck Surgery, Stanford University, Stanford, CA, USA.

Jolien M Sweere (JM)

Department of Medicine, Infectious Diseases, Stanford University, Stanford, CA, USA.

Daniel Pletzer (D)

Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.
Department of Microbiology and Immunology, University of Otago, Dunedin, New Zealand.

Robert E Hancock (RE)

Department of Microbiology and Immunology, University of British Columbia, Vancouver, BC, Canada.

Paul L Bollyky (PL)

Department of Medicine, Infectious Diseases, Stanford University, Stanford, CA, USA.

Peter L Santa Maria (PL)

Department of Otolaryngology, Head and Neck Surgery, Stanford University, Stanford, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH